Showing 321-330 of 1374 results for "".
MATV News: New Restylane Fillers FDA Approved; Hyperhidrosis and Anxiety; Educating Plastic Surgery Patients
https://modernaesthetics.com/series/matv-news/new-restylane-fillers-fda-approved-hyperhidrosis-and-anxiety-educating-plastic-surgery-patients/33400/The FDA approved two new Galderma Restylane fillers for the treatment of nasolabial folds or laugh lines in patients over the age of 21. Patients with hyperhidrosis may be more likely to be anxious or depressed and you may want to council cosmetic surgery patients to stop prior to undergoing proceduMATV News: Juvéderm Volbella XC Now Available; Gluteal Fat Grafting Task Force Forms
https://modernaesthetics.com/series/matv-news/matv-news-juv-derm-volbella-xc-now-available-gluteal-fat-grafting-task-force-forms--estovege/33356/Juvéderm Volbella XC is now available for lip augmentation and correction of perioral rhytids. Also, the Aesthetic Surgery Education and Research Foundation forms a Gluteal Fat Grafting Task Force in response to high mortality rates seen with Brazilian butt lifts, Biologica Technologies introduces iMATV News: Dr. Ivo Pitanguy Dies, ISAPS Says US Tops in Plastic Surgery
https://modernaesthetics.com/series/matv-news/matv-news-dr-ivo-pinanguy-dies-isaps-says-us-tops-in-plastic-surgery/33402/Losing a Legend: MATV News covers the death of plastic surgery pioneer Dr. Ivo Pitanguy and explores the expected growth of the body contouring market. Plus, the FDA grants new clearances to Syneron, while ISAPS confirms that the US remains the most popular place in the world for plastic surgery. AnMATV News: VCS Highlights; Volbella XC Approved
https://modernaesthetics.com/series/matv-news/matv-news-vcs-highlights-volbella-xc-approved/33409/In this edition of MATV News, from the editors of Modern Aesthetics® magazine, we cover the recent Vegas Cosmetic Surgery meeting as well as the FDA approval of Allergan's Juvéderm Volbella XC for lip augmentation and for correction of perioral rhytids. Also in this episode, Galderma celebrates RestMATV News: Facial Rejuvenation Market Growth; Aesthetic Industry Updates
https://modernaesthetics.com/series/matv-news/matv-news-facial-rejuvenation-market-growth-aesthetic-industry-updates/33415/In this edition of MATV News, from the editors of Modern Aesthetics® magazine, we cover a new report that predicts growth in the facial rejuvenation market and discuss that the FDA green lit Mentor's ATHENA breast implant trial. Also in this edition, a new oculoplastics app from Volk Eye Check and iMATVNews: RT002 Data From Revance Abdominoplasty Risks PFD Patch for Tattoo Removal
https://modernaesthetics.com/series/matv-news/matvnews-rt002-data-from-revance-abdominoplasty-risks-pfd-patch-for-tattoo-removal/33391/In this edition of MATV News, from the editors of Modern Aesthetics® magazine, a look at new data for injectable RT002 from Revance and an update on abdominoplasty risks. Plus, Zwivel and CareCredit team up, and a new PFD patch eases tattoo removal. Talk back: HIPAA Security.MATV News: Allergan to Acquire Kythera; VCS Update
https://modernaesthetics.com/series/matv-news/matv-episode-1-20150623/33432/In this premiere edition of MATV News, from the editors of Modern Aesthetics® magazine, we take a look at the Allergan deal to acquire Kythera Biopharmaceuticals and get insights about the Vegas Cosmetic Surgery & Aesthetic Dermatology. Also in this edition, Radiesse gets FDA approval for hands,Three Ways: Summer Slumps: How Can You Sail Through?
https://modernaesthetics.com/topics/practice-development/summer-slumps-how-can-you-sail-through/34028/If business is lagging during the dog days, here's advice on making the most of the open time.Bonus and Incentive Programs
https://modernaesthetics.com/ma-issues-index/2017-may-june/bonus-and-incentive-programs/34282/Profit-sharing legalities and potential pitfalls.Want to be a Medical Director at a Medical Spa? Beware
https://modernaesthetics.com/ma-issues-index/2014-mar-apr/want-to-be-a-medical-director-at-a-medical-spa-beware/34659/With the title comes responsibility—and liability